Sanders Morris Harris LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 1,700 shares of the medical research company’s stock, valued at approximately $795,000.

Several other large investors have also modified their holdings of TMO. Bay Harbor Wealth Management LLC increased its stake in Thermo Fisher Scientific by 23.0% during the second quarter. Bay Harbor Wealth Management LLC now owns 139 shares of the medical research company’s stock worth $50,000 after acquiring an additional 26 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Thermo Fisher Scientific by 2.8% in the third quarter. Wedge Capital Management L L P NC now owns 942 shares of the medical research company’s stock valued at $416,000 after buying an additional 26 shares in the last quarter. Engrave Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 20.9% in the second quarter. Engrave Wealth Partners LLC now owns 162 shares of the medical research company’s stock valued at $58,000 after buying an additional 28 shares in the last quarter. Koshinski Asset Management Inc. grew its stake in shares of Thermo Fisher Scientific by 0.5% in the second quarter. Koshinski Asset Management Inc. now owns 5,299 shares of the medical research company’s stock valued at $1,920,000 after buying an additional 28 shares in the last quarter. Finally, Allred Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 3.5% in the third quarter. Allred Capital Management LLC now owns 852 shares of the medical research company’s stock valued at $376,000 after buying an additional 29 shares in the last quarter. 88.12% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on TMO. UBS Group increased their target price on Thermo Fisher Scientific from $385.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. SVB Leerink increased their target price on Thermo Fisher Scientific from $455.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 11th. JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $460.00 to $480.00 and gave the company an “overweight” rating in a report on Monday, October 5th. BTIG Research increased their price target on Thermo Fisher Scientific from $372.00 to $475.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Finally, Credit Suisse Group increased their price target on Thermo Fisher Scientific from $425.00 to $432.00 and gave the company a “neutral” rating in a report on Friday, September 11th. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $452.27.

In related news, COO Mark Stevenson sold 22,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $420.16, for a total value of $9,243,520.00. Following the sale, the chief operating officer now owns 34,561 shares of the company’s stock, valued at approximately $14,521,149.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Peter E. Hornstra sold 3,337 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $418.82, for a total value of $1,397,602.34. Following the completion of the sale, the chief accounting officer now directly owns 19,862 shares in the company, valued at approximately $8,318,602.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 173,868 shares of company stock worth $71,253,379. 0.44% of the stock is currently owned by company insiders.

NYSE:TMO traded up $4.03 during trading hours on Friday, reaching $468.59. 1,070,263 shares of the stock were exchanged, compared to its average volume of 1,656,574. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69. The firm has a 50 day simple moving average of $433.77 and a 200-day simple moving average of $378.29. Thermo Fisher Scientific Inc. has a 52 week low of $250.21 and a 52 week high of $473.84. The stock has a market capitalization of $185.37 billion, a P/E ratio of 50.71, a P/E/G ratio of 1.88 and a beta of 1.01.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The company had revenue of $6.92 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the business posted $3.04 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 15.27 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Further Reading: What Are Treasury Bonds?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.